Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response

Shakiba, Yasmin; Vorobyev, Pavel O.; Yusubalieva, Gaukhar M.; Kochetkov, D. V.; Zajtseva, Ksenia V.; Valikhov, Marat P.; Kalsin, Vladimir A.; Забозлаев, Ф Г; Semkina, Alevtina S.; Troitskiy, A. V.; Baklaushev, V. P.; Chumakov, P. M.; Lipatova, Anastasiya V.

doi:10.1016/j.omto.2023.05.002

Molecular Therapy - Oncolytics

2023

DOI: 10.1016/j.omto.2023.05.002

|View full text |Cite

Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response

Yasmin Shakiba

Pavel O. Vorobyev

Gaukhar M. Yusubalieva

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shakiba et al developed recombinant variants of the oncolytic vaccinia virus LIVP strain expressing IL-15 or IL-15 Rα to stimulate IL-15-dependent immune cells. 4 They evaluated their oncolytic activity either alone or in combination with each other in vitro and in vivo using the murine CT26 colon carcinoma and 4T1 breast carcinoma. LIVP (vaccinia virus Lister strain from the Institute of Virus Preparation, Moscow, Russia) is an attenuated variant with excellent oncolytic properties.…”

mentioning

confidence: 99%

Oncolytic virotherapy targeting the IL15 pathway

Yoo,

Heo

2023

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

mentioning

confidence: 99%

Oncolytic virotherapy targeting the IL15 pathway

Yoo,

Heo

2023

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Oncolytic virus-based combination therapy in breast cancer

Bahreyni,

Mohamud,

Luo

2024

Cancer Letters

View full text Add to dashboard Cite

Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies

Zinovieva,

Ryapolova,

Karabelsky

et al. 2024

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Oncolytic viruses (OVs) represent a targeted anti-cancer therapy approach due to their ability not only to selectively infect and destroy malignant cells but also to induce an immune response. Vesicular stomatitis virus (VSV) offers a promising platform due to its low prevalence and pathogenicity in humans, lack of pre-existing immunity, easily manipulated genome, rapid growth to high titers in a broad range of cell lines, and inability to integrate into the host genome. However, despite its many advantages, many unresolved problems remain: problematic production based on the reverse genetics system, oncological selectivity, and the overall effectiveness of VSV monotherapy. This review will discuss various attempts at viral genome modifications aimed at improving the oncolytic properties of VSV. These strategies include inhibition of viral genes, modification of genes responsible for targeting cancer cells over healthy ones, insertion of foreign genes for boosting immune response, and changing the order of viral and inserted foreign genes. In addition, possible ways to improve VSV-based anti-tumor therapy and achieve higher efficiency will be considered by evaluating the effectiveness of various delivery methods as well as discussing treatment options by combining VSV with other groups of anticancer drugs.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response

Cited by 5 publications

References 56 publications

Oncolytic virotherapy targeting the IL15 pathway

Oncolytic virotherapy targeting the IL15 pathway

Oncolytic virus-based combination therapy in breast cancer

Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies

Contact Info

Product

Resources

About